基于肝星状细胞调控的肝纤维化治疗机制相关研究概述  

An Overview of Therapeutic Mechanism of Hepatic Fibrosis Based on Hepatic Stellate Cell Regulation

作　　者：牛媛媛 汪龙德 毛兰芳[1] 胥文娟[1] 张萍 符博雅 NIU Yuanyuan;WANG Longde;MAO Lanfang;XU Wenjuan;ZHANG Ping;FU Boya(Gansu University of Chinese Medicine,Lanzhou 730000,China;Department of Gastroenterology,Affiliated Hospital of Gansu University of Chinese Medicine,Lanzhou 730020,China)

机构地区：[1]甘肃中医药大学,兰州730000 [2]甘肃中医药大学附属医院消化科,兰州730020

出　　处：《医学综述》2022年第1期40-44,共5页Medical Recapitulate

基　　金：敦煌医学与转化教育部重点实验室开放基金项目(DHYX18-27);甘肃省中医方药挖掘与创新转化重点实验室开放课题(zyzx-2020-02)。

摘　　要：肝纤维化是多种急慢性肝病进一步发展至肝硬化、肝细胞癌的必经阶段,已成为该领域的研究重点与热点。肝星状细胞(HSCs)的激活是肝纤维化发生发展过程中的显著驱动因素,调控HSCs激活前的干预阶段(预防或抑制HSCs激活)、HSCs激活后的中间阶段(促进HSCs表型转化与免疫清除)及HSCs衰退的后期阶段(促进HSCs凋亡与诱导HSCs衰老)等分子生物学过程可作为肝纤维化治疗的潜在策略之一。重视HSCs在肝纤维化发生发展中的核心地位,可为肝纤维化的预防、诊断、治疗等干预策略的确立提供新思路。Hepatic fibrosis is a necessary stage for a variety of acute and chronic liver diseases in the development into liver cirrhosis and hepatocellular carcinoma,which has become the research focus and hotspot in this field.The activation of hepatic stellate cells(HSCs)is a significant driving factor in the occurrence and development of hepatic fibrosis.Regulating the intervention stage before HSCs activation(preventing or inhibiting HSCs activation),the intermediate stage after HSCs activation(promoting HSCs phenotypic transformation and immune clearance)and the later stage of HSCs decline(promoting HSCs apoptosis and inducing HSCs aging)and other molecular biological processes can be used as one of the potential strategies for the treatment of liver fibrosis.Paying attention to the core position of HSCs in the occurrence and development of hepatic fibrosis can provide new ideas for the establishment of prevention,diagnosis and treatment intervention strategies of hepatic fibrosis.

关 键 词：肝纤维化 肝星状细胞 表型转化 

分 类 号：R575.2[医药卫生—消化系统]